RxDoctor Payments Data

Matthew Greenblatt

Clinical Pathology/Laboratory Medicine · New York, NYNPI 1043653405

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,998 of the $19,240 with a category attached, or 72.8%. Amgen accounts for 81.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $12,415, more than ten times the $550 reported in 2019.

$19,240in general payments, 2019–2025

Across 17 payments — averaging $1131.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$16K
  • BD$2K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Illumina, Inc.$420
  • Biofire Diagnostics, LLC$325
  • Stryker$271

What the payments were for

  • Consulting fees$4,70924%
  • Speaking & faculty fees$13,99873%
  • Food & beverage$5333%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen4$15,601
BD3$1,523
Musculoskeletal Transplant Foundation Inc.2$1,100
Illumina, Inc.1$420
Biofire Diagnostics, LLC1$325
Stryker6$271

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,240 in reported general payments places this provider in the 85th percentile of 37 clinical pathology/laboratory medicine providers in New York.

See all clinical pathology/laboratory medicine providers in New York

Medicare billing

Part B allowed, 2024
$53,515
Medicare patients
995
Services billed
2,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →